Abstract
Dermatans are endogenous glycosaminoglycans which catalyze thrombin-heparin cofactor II interaction (1) and may promote fibrinolysis by induction of PA release (2). In different animal models dermatans have been shown to prevent thrombus formation (3,4,5,6). Since they are less haemorrhagic than standard heparin (4,7), dermatans may represent a class of antithrombotic agents with reduced bleeding risk. Low molecular weight heparins have longer biological halflives than standard heparins (8). Recently it has been found that potentiation of thrombin-heparin cofactor II interaction by a low molecular weight dermatan sulfate lasted longer than that induced by a native dermatan sulfate, both in rats and in monkeys (9), suggesting that the two molecular weight forms have different pharmacokinetic profiles. The aim of the present study was to investigate whether the antithrombotic activity of Desmin 370, a new low molecular weight dermatan sulfate (IO, 11,12) and DS435, the native dermatan, was influenced by route of administration, In addition, the concentration-time curves of the two dermatans, given s.c., were evaluated ex vivo by a coagulation assay.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call